Literature DB >> 19159062

Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease.

Kersi J Bharucha1, Joyce K Friedman, Andrea S Vincent, Elliott D Ross.   

Abstract

Ceruloplasmin functions as a ferroxidase in iron metabolism. Parkinson's disease (PD) is characterized by an increase in brain iron. We postulated that lower circulating ceruloplasmin levels in PD would result in rapid brain iron accumulation and an earlier age of onset. Consecutive PD patients were separated into subgroups with younger (< or = 60 years, n = 62) and older ages of onset (> 60, n = 29), and compared to non-PD controls (n = 40). A one-way ANOVA comparing ceruloplasmin levels showed a very robust effect [F(2,128) = 46.4, p < 1e-99]. Post hoc analysis demonstrated that the younger-onset PD subgroup [22.0 mg/dl +/- 6.5 SD] had a lower mean ceruloplasmin level compared to the older-onset PD subgroup [35.7 +/- 10.4] and controls [35.6 +/- 8.4], whose levels did not differ from each other. Ceruloplasmin levels showed robust correlation with age of onset in all 91 PD patients [r = 0.56, r(2) = 0.31, p < 0.0001] but not in the non-PD controls [r = 0.16, r(2) = 0.03, not significant]. Mode of onset and duration of PD showed no relationship to ceruloplasmin. Serum copper and ferritin, available in most patients, did not differ between the PD subgroups. Younger-onset PD patients have significantly lower levels of serum ceruloplasmin compared to those with older-onset PD. Ceruloplasmin may play a role in the etiopathogenesis of younger-onset PD patients and merits further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19159062     DOI: 10.1007/s00415-009-0063-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  Influence of age and sex on serum copper and ceruloplasmin levels.

Authors:  A A Yunice; R D Lindeman; A W Czerwinski; M Clark
Journal:  J Gerontol       Date:  1974-05

2.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

3.  Determinants of serum copper, zinc and selenium in healthy subjects.

Authors:  M Ghayour-Mobarhan; A Taylor; S A New; D J Lamb; G A A Ferns
Journal:  Ann Clin Biochem       Date:  2005-09       Impact factor: 2.057

4.  The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro.

Authors:  Kyung Sik Kim; Soo Young Choi; Hyeok Yil Kwon; Moo Ho Won; Tae-Cheon Kang; Jung Hoon Kang
Journal:  Biochimie       Date:  2002-07       Impact factor: 4.079

Review 5.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

6.  Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease.

Authors:  M C Boll; J Sotelo; E Otero; M Alcaraz-Zubeldia; C Rios
Journal:  Neurosci Lett       Date:  1999-04-23       Impact factor: 3.046

Review 7.  Brain iron metabolism.

Authors:  Tracey A Rouault; Sharon Cooperman
Journal:  Semin Pediatr Neurol       Date:  2006-09       Impact factor: 1.636

8.  Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease.

Authors:  G Tórsdóttir; J Kristinsson; S Sveinbjörnsdóttir; J Snaedal; T Jóhannesson
Journal:  Pharmacol Toxicol       Date:  1999-11

Review 9.  The relevance of iron in the pathogenesis of Parkinson's disease.

Authors:  Mario E Götz; Kay Double; Manfred Gerlach; Moussa B H Youdim; Peter Riederer
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

10.  Effect of age on the activity of ceruloplasmin of human blood.

Authors:  I Semsei; F Jeney; T Fülöp
Journal:  Arch Gerontol Geriatr       Date:  1993 Sep-Oct       Impact factor: 3.250

View more
  18 in total

1.  Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson's disease.

Authors:  Na Zhao; Jianqiu Xiao; Zhiyong Zheng; Guoqiang Fei; Feng Zhang; Lirong Jin; Chunjiu Zhong
Journal:  Neurosci Bull       Date:  2015-03-10       Impact factor: 5.203

2.  Ceruloplasmin is Involved in the Nigral Iron Accumulation of 6-OHDA-Lesioned Rats.

Authors:  Jun Wang; Mingxia Bi; Junxia Xie
Journal:  Cell Mol Neurobiol       Date:  2015-02-06       Impact factor: 5.046

3.  ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism.

Authors:  Leah C Beauchamp; Xiang M Liu; Laura J Vella; Paul A Adlard; Ashley I Bush; David I Finkelstein; Kevin J Barnham
Journal:  Neurotherapeutics       Date:  2022-09-29       Impact factor: 6.088

4.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

Review 5.  Brain Iron Metabolism Dysfunction in Parkinson's Disease.

Authors:  Hong Jiang; Jun Wang; Jack Rogers; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-04-02       Impact factor: 5.590

6.  Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases.

Authors:  S Mariani; M Ventriglia; I Simonelli; G Spalletta; S Bucossi; M Siotto; F Assogna; J M Melgari; F Vernieri; R Squitti
Journal:  Front Aging Neurosci       Date:  2013-08-05       Impact factor: 5.750

7.  Physical activity is linked to ceruloplasmin in the striatum of intact but not MPTP-treated primates.

Authors:  Rehana K Leak; Krassimira A Garbett; Amanda M Dettmer; Zhiming Zhang; Károly Mirnics; Judy L Cameron
Journal:  Cell Tissue Res       Date:  2012-09-02       Impact factor: 5.249

Review 8.  Wilson's disease and other neurological copper disorders.

Authors:  Oliver Bandmann; Karl Heinz Weiss; Stephen G Kaler
Journal:  Lancet Neurol       Date:  2015-01       Impact factor: 44.182

9.  Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity.

Authors:  Akiyo Hineno; Kazuma Kaneko; Kunihiro Yoshida; Shu-ichi Ikeda
Journal:  Neurochem Res       Date:  2011-06-26       Impact factor: 3.996

10.  Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivo.

Authors:  Jessica M Posimo; Amanda M Titler; Hailey J H Choi; Ajay S Unnithan; Rehana K Leak
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.